A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma
PRIMARY OBJECTIVE:
The primary objective of this study is to determine whether administration of bortezomib
leads to an increase in cellular autophagy, as determined by electron micrographs of
peripheral blood lymphocytes and primary myeloma cells in patients receiving single-agent
bortezomib.
SECONDARY OBJECTIVES
1. To determine the optimal timing of autophagy assessments for patients receiving
bortezomib.
2. To explore whether high levels of autophagy are associated with resistance to
bortezomib therapy.
3. To validate our primary assay by confirming baseline stability of the number of
autophagic vesicles per cell
4. To compare results of autophagy measurements in peripheral blood mononuclear cells and
bone marrow plasma cells
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment
Number of Adverse Events
Yes
Dan Vogl, MD
Principal Investigator
Abramson Cancer Center of the University of Pennsylvania
United States: Institutional Review Board
UPCC 05411
NCT01594242
April 2012
April 2013
Name | Location |
---|---|
Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania 19104-4283 |